stockrow
Saturday 7 November 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024.
- Revenue
- +3.50%
- EPS
- +41.5%
- Free cash flow
- +4.40%
Quarter to June 2026, against a year earlier
4.61
0.16
+3.60%
Follow PRME
Alert me
Prime Medicine, Inc. (PRME) P/E ratio
Prime Medicine, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ALMS Alumis Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| PRME Prime Medicine, Inc. | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| MGTX MeiraGTx Holdings PLC compare | 11.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)